Bristol Myers Squibb announced that it will present new data from its cardiovascular portfolio at the upcoming American Heart Association’s (AHA) Scientific Sessions 2025, scheduled for November 7–10, 2025, in New Orleans, Louisiana. The presentations will include new analyses from a long-term extension study and real-world evidence demonstrating how Camzyos® (mavacamten) continues to advance the treatment landscape for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Additional data will also be shared from the BMS–Johnson & Johnson Collaboration on milvexian.
“Building on our 70-year legacy of cardiovascular innovation, Camzyos has reset the baseline for treating adults with symptomatic oHCM, allowing physicians and patients to move beyond symptom management to a treatment that has consistently demonstrated an ability to significantly reduce obstruction, impact cardiac structure, and improve symptoms,” said Cristian Massacesi, MD, Executive Vice President, Chief Medical Officer and Head of Development, Bristol Myers Squibb. “The new data we are presenting at the American Heart Association’s Scientific Sessions 2025 highlight the consistent and sustained results we’ve seen in our long-term extension study over nearly four years and strengthen the significant body of real-world effectiveness and safety data for Camzyos.”
Currently, Camzyos is approved in over 50 countries and regions across five continents and is prescribed by thousands of healthcare professionals worldwide. In the U.S., more than 4,000 physicians have prescribed Camzyos to over 20,000 patients since its launch. The therapy is now established as a standard of care for treating New York Heart Association (NYHA) class II–III symptomatic oHCM.
Key data presentations at AHA 2025 will include:
· EXPLORER-LTE (MAVA Long-Term Extension) Study: Analysis of long-term outcomes assessing the effects of Camzyos on obstruction, cardiac structure, and biomarkers over nearly four years, stratified by disease duration.
· Camzyos REMS Program Analysis: Evaluation of patient-level data from nearly three years post-launch, representing the largest real-world safety dataset of U.S. patients treated with Camzyos, including those with at least two years of follow-up.
· Real-World Healthcare Resource Utilization Study: Assessment of hospitalization and emergency room visit rates in U.S. patients with symptomatic oHCM, using linked claims and electronic health record data.
· COLLIGO-HCM and MARVEL-HCM Studies: Real-world data highlighting the effectiveness and safety of Camzyos monotherapy across diverse patient populations — COLLIGO-HCM being a global, racially diverse observational study across four continents, and MARVEL-HCM a multicenter U.S. study spanning both academic and community settings.
· ODYSSEY-HCM Trial: Additional analyses exploring Camzyos in symptomatic non-obstructive hypertrophic cardiomyopathy (nHCM) will be presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions, co-located with the AHA meeting on November 7, 2025.
Select abstracts from Bristol Myers Squibb and the BMS–Johnson & Johnson Collaboration will be featured during the event. For more details on BMS’s scientific approach and cardiovascular research, visit the company’s official website at BMS.com.
Also Read
